Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma

Melissa Bennett, Melinda Tea, Briony Gliddon, John Toubia, Robert Orlowski, Craig Wallington-Beddoe, Stuart Pitson

Research output: Contribution to journalMeeting Abstractpeer-review


Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism.
Original languageEnglish
Article number3019
Pages (from-to)S58
Number of pages1
JournalExperimental Hematology
Issue numberSupplement
Publication statusPublished - 2019
Event48th ISEH Annual Scientific Meeting - Brisbane Convention & Exhibition Centre, Brisbane, Australia
Duration: 22 Aug 201925 Aug 2019


  • multiple myeloma
  • Sphingosine kinase 2
  • Bortezomib resistance
  • 5TGM1
  • K145


Dive into the research topics of 'Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma'. Together they form a unique fingerprint.

Cite this